Dexco (BVMF:DXCO3) Full Year 2024 Results
Key Financial Results
- Revenue: R$8.23b (up 12% from FY 2023).
- Net income: R$172.4m (down 78% from FY 2023).
- Profit margin: 2.1% (down from 11% in FY 2023). The decrease in margin was driven by higher expenses.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Dexco Revenues Beat Expectations
Revenue exceeded analyst estimates by 2.7%.
Looking ahead, revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Global Forestry industry.
Performance of the market in Brazil.
The company's shares are down 3.5% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Dexco (at least 1 which is a bit unpleasant), and understanding them should be part of your investment process.
Valuation is complex, but we're here to simplify it.
Discover if Dexco might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.